Vistagen therapeutics stock.

Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ...William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on …SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 8, 2022-- Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (Vistagen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) …Benzinga - by Vandana Singh, Benzinga Editor. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage …

Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly …Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results.The pharmaceutical producer has been struggling all year, dipping into penny ...

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.05 per share a year ago.

Vistagen Therapeutics Inc. Real-Time Quotes. 3.66. BATS BZX Real-Time Price. As of 2:09pm ET. +0.28 / +8.28%. Today’s Change. 1.62. Today ||| 52-Week Range.The VistaGen Therapeutics Inc stock price gained 7.16% on the last trading day (Friday, 24th Nov 2023), rising from $3.35 to $3.59. During the last trading day the stock fluctuated 8.30% from a day low at $3.37 to a day high of $3.65. The price has risen in 8 of the last 10 days and is up by 24.22% over the past 2 weeks.Vistagen Therapeutics, Inc. 3.7200 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...Fasedienol was also found to be well-tolerated with a favorable safety profile, according to Vistagen. The biotech’s stock skyrocketed 1,272% from market close Friday, rising from $1.68 per ...

Nov 15, 2022 · The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ...

With FDA feedback confirming the acceptable use of the LSAS as a primary efficacy endpoint, Vistagen is positioned to finalize key components of its potential New Drug Application (NDA)-enabling development program for fasedienol for treatment of SAD. Dr. Michael R. Liebowitz, a Columbia University psychiatrist, former director and founder of ...

Dec 1, 2023 · VTGN Earnings Date and Information. Vistagen Therapeutics last issued its quarterly earnings results on November 9th, 2023. The reported ($0.66) earnings per share for the quarter. The company earned $0.28 million during the quarter. Vistagen Therapeutics has generated $0.00 earnings per share over the last year. Vistagen Therapeutics, Inc. 3.7200 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...Subsidiaries VistaGen Therapeutics, Inc., a California corporation d/b/a VistaStem (VistaStem), is our wholly owned subsidiary. For the relevant periods, our Consolidated Financial Statements in this Quarterly Report on Form 10-Q (Report) ... Stock-based compensation expense for the quarter ended December 31, ...Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently ...Track VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors 3.5900. -0.1000. -2.71%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript November 10, 2023 Operator: Good day, everyone and …

Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ...SOUTH SAN FRANCISCO, Calif., December 21, 2022--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with ...5 hours ago · William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ... VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Vistagen Therapeutics Inc ( VTGN) is up 6.73% today. VTGN has an Overall Score of 56. Find out what this means to you and get the rest of the rankings on VTGN! VTGN stock closed at $3.12 and is up $0.21 during pre-market trading. Pre-market tends to be more volatile due to significantly lower volume as most investors only trade between standard ...

Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ... Feb 7, 2023 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.05 per share a year ago. Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ... VistaGen Therapeutics (NASDAQ: VTGN) stock is falling hard on Friday after the clinical-stage biopharmaceutical company reported poor results from a Phase 3 study. That clinical trial covers PH94B ...Vistagen’s fasedienol (PH94B) is a first-in-class, rapid-onset investigational neuroactive pherine nasal spray in Phase 3 clinical development for acute treatment of social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed novel mechanism of action (MOA) of fasedienol is fundamentally ...By Colin Kellaher. Vistagen Therapeutics shares tumbled on Monday after the clinical-stage biopharmaceutical company said it was raising $100 million in a public offering of stock and warrants.Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly …Track VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...

Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly …

VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more ...Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen ... VistaGen Therapeutics Hype Timeline. VistaGen Therapeutics is at this time traded for 3.65. The entity has historical hype elasticity of -0.17 and average ...VistaGen Therapeutics Inc (NASDAQ:VTGN) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) …Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.Mar 9, 2023 · Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $179.6 thousand and a GAAP net loss of $9.76 million. Vistagen’s fasedienol (PH94B) is a first-in-class, rapid-onset investigational neuroactive pherine nasal spray in Phase 3 clinical development for acute treatment of social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed novel mechanism of action (MOA) of fasedienol is fundamentally ...On average, Wall Street analysts predict. that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock price prediction forecasts a potential upside of 484.96% from the current VTGN share price of $3.59.Psychedelic therapy, also known as psychedelic-assisted psychotherapy (PAP), combines traditional talk therapy with a psychedelic substance, such as LSD, psilocybin, ayahuasca, or MDMA.

Price Action: VTGN shares are up 13.42% at $4.14 on the last check Monday. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ:VTGN), a …Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders.Discover Vistagen Therapeutics' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers. ... CEO & Director exercised options to buy US$120k worth of stock. May 17. VistaGen Announces Key Regulatory Update on Ph94b for the Acute Treatment of Social Anxiety …The recent price decline of 15% in VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) stock may have disappointed insiders who bought US$190k worth of shares at an average price of US$0.17 in the past 12 ...Instagram:https://instagram. wells fargo financial healthpins stock forecastsso sharesbest performing stock 2023 See today’s best-performing stocks on TipRanks >> Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $179.6 ... metlife dental plan reviewswhat are fang stocks Benzinga - by Vandana Singh, Benzinga Editor. William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety disorder (SAD) and other mental health conditions.. The lead product … meta mau Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that company management will present and host one-on-one meetings at the Stifel 2023 Healthcare Conference taking place November 14 – 15, 2023 at the Lotte New ...Dec 1, 2023 · Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly Results; Section 16 Filings; Corporate Governance Executive Team; Board Committees; Documents & Charters